In a stratification analysis according to ALT > 30 U/L, luseogliflozin significantly decreased fatty liver index, NAFLD liver fat score, and hepatic steatosis index after 24 weeks (Figs. 3A, 3B, and 3C). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.